🚀 VC round data is live in beta, check it out!
Dr Reddy's Laboratories Overview
About Dr Reddy's Laboratories
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Founded
1984
HQ
Employees
27.8K
Website
Sectors
Financials (LTM)
EV
$11B
Dr Reddy's Laboratories Financials
Dr Reddy's Laboratories reported last 12-month revenue of $4B and EBITDA of $846M.
In the same LTM period, Dr Reddy's Laboratories generated $2B in gross profit, $846M in EBITDA, and $544M in net income.
Revenue (LTM)
Dr Reddy's Laboratories P&L
In the most recent fiscal year, Dr Reddy's Laboratories reported revenue of $4B and EBITDA of $1B.
Dr Reddy's Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $846M | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $544M | XXX | $662M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $292M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dr Reddy's Laboratories Stock Performance
Dr Reddy's Laboratories has current market cap of $11B, and enterprise value of $11B.
Market Cap Evolution
Dr Reddy's Laboratories' stock price is $13.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $11B | 1.5% | XXX | XXX | XXX | $0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDr Reddy's Laboratories Valuation Multiples
Dr Reddy's Laboratories trades at 2.9x EV/Revenue multiple, and 12.9x EV/EBITDA.
EV / Revenue (LTM)
Dr Reddy's Laboratories Financial Valuation Multiples
As of April 18, 2026, Dr Reddy's Laboratories has market cap of $11B and EV of $11B.
Equity research analysts estimate Dr Reddy's Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr Reddy's Laboratories has a P/E ratio of 20.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 12.9x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBIT | 16.7x | XXX | 13.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | 5.3x | XXX | XXX | XXX |
| P/E | 20.3x | XXX | 16.7x | XXX | XXX | XXX |
| EV/FCF | 27.2x | XXX | 84.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dr Reddy's Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dr Reddy's Laboratories Margins & Growth Rates
Dr Reddy's Laboratories' revenue in the last 12 month grew by 4%.
Dr Reddy's Laboratories' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Dr Reddy's Laboratories' rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr Reddy's Laboratories' rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dr Reddy's Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | (3%) | XXX | (18%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | 25% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dr Reddy's Laboratories Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dr Reddy's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| RemeGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Cipla | XXX | XXX | XXX | XXX | XXX | XXX |
| Exelixis | XXX | XXX | XXX | XXX | XXX | XXX |
| Lupin | XXX | XXX | XXX | XXX | XXX | XXX |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr Reddy's Laboratories M&A Activity
Dr Reddy's Laboratories acquired XXX companies to date.
Last acquisition by Dr Reddy's Laboratories was on XXXXXXXX, XXXXX. Dr Reddy's Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dr Reddy's Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDr Reddy's Laboratories Investment Activity
Dr Reddy's Laboratories invested in XXX companies to date.
Dr Reddy's Laboratories made its latest investment on XXXXXXXX, XXXXX. Dr Reddy's Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dr Reddy's Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dr Reddy's Laboratories
| When was Dr Reddy's Laboratories founded? | Dr Reddy's Laboratories was founded in 1984. |
| Where is Dr Reddy's Laboratories headquartered? | Dr Reddy's Laboratories is headquartered in India. |
| How many employees does Dr Reddy's Laboratories have? | As of today, Dr Reddy's Laboratories has over 27K employees. |
| Who is the CEO of Dr Reddy's Laboratories? | Dr Reddy's Laboratories' CEO is M. V. Ramana. |
| Is Dr Reddy's Laboratories publicly listed? | Yes, Dr Reddy's Laboratories is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Dr Reddy's Laboratories? | Dr Reddy's Laboratories trades under DRREDDY ticker. |
| When did Dr Reddy's Laboratories go public? | Dr Reddy's Laboratories went public in 2003. |
| Who are competitors of Dr Reddy's Laboratories? | Dr Reddy's Laboratories main competitors are RemeGen, Cipla, Exelixis, Lupin. |
| What is the current market cap of Dr Reddy's Laboratories? | Dr Reddy's Laboratories' current market cap is $11B. |
| What is the current revenue of Dr Reddy's Laboratories? | Dr Reddy's Laboratories' last 12 months revenue is $4B. |
| What is the current revenue growth of Dr Reddy's Laboratories? | Dr Reddy's Laboratories revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Dr Reddy's Laboratories? | Current revenue multiple of Dr Reddy's Laboratories is 2.9x. |
| Is Dr Reddy's Laboratories profitable? | Yes, Dr Reddy's Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr Reddy's Laboratories? | Dr Reddy's Laboratories' last 12 months EBITDA is $846M. |
| What is Dr Reddy's Laboratories' EBITDA margin? | Dr Reddy's Laboratories' last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Dr Reddy's Laboratories? | Current EBITDA multiple of Dr Reddy's Laboratories is 12.9x. |
| What is the current FCF of Dr Reddy's Laboratories? | Dr Reddy's Laboratories' last 12 months FCF is $400M. |
| What is Dr Reddy's Laboratories' FCF margin? | Dr Reddy's Laboratories' last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Dr Reddy's Laboratories? | Current FCF multiple of Dr Reddy's Laboratories is 27.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.